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https://doi.org/10.1053/j.gastro.2020.03.025BACKGROUND & AIMS: Sessile serrated polyps (SSPs) could
account for a substantial proportion of colorectal cancers. We
aimed to increase clarity on SSP prevalence and clinical features.
METHODS: We performed a systematic review of MEDLINE,
Web of Science, Embase, and Cochrane databases for original
studies published in English since 2000. We included studies of
different populations (United States general or similar), in-
terventions (colonoscopy, autopsy), comparisons (world re-
gions, alternative polyp definitions, adenoma), outcomes
(prevalence, clinical features), and study designs (cross-
sectional). Random-effects regression was used for meta-
analysis where possible. RESULTS: We identified 74 relevant
colonoscopy studies. SSP prevalence varied byworld region, from
2.6% in Asia (95% confidence interval [CI], 0–5.9) to 10.5% in
Australia (95% CI, 2.8–18.2). Prevalence values did not differ
significantly between the United States and Europe (P¼ .51); the
pooled prevalence was 4.6% (95% CI, 3.4–5.8), and SSPs
accounted for 9.4% of polyps with malignant potential (95% CI,
6.6–12.3). The mean prevalence was higher when assessed
through high-performance examinations (9.1%; 95% CI, 4.0–
14.2; P ¼ .04) and with an alternative definition of clinically
relevant serrated polyps (12.3%; 95% CI, 9.3–15.4; P < .001).
Increases in prevalencewith agewere not statistically significant,
and prevalence did not differ significantly by sex. Compared with
adenomas, a higherproportion of SSPswere solitary (69.0%;95%
CI, 45.9–92.1; P¼ .08), with diameters of 10mmormore (19.3%;
95% CI, 12.4–26.2; P ¼ .13) and were proximal (71.5%; 95% CI,63.5–79.5; P¼ .008). The mean ages for detection of SSP without
dysplasia, with any or low-grade dysplasia, and with high-grade
dysplasia were 60.8 years, 65.6 years, and 70.2 years, respec-
tively. The range for proportions of SSPs with dysplasia was
3.7%–42.9% across studies, possibly reflecting different study
populations. CONCLUSIONS: In a systematic review, we found
that SSPs are relatively uncommon compared with adenoma.
More research is needed on appropriate diagnostic criteria,
variations in detection, and long-term risk.Keywords: Colon Cancer; Neoplasm; PICOS; US.
olorectal cancer (CRC) is a leading cause of cancer
1Cdeaths. The disease develops primarily from pre-
cancerous lesions called adenomas.2 In a series of seminal
papers from the 1970s and 1980s,3,4 this process was first
characterized as relatively slow, with many adenomas
WHAT YOU NEED TO KNOW
BACKGROUND & CONTEXT
Sessile serrated polyps (SSPs) might account for 30% of
colorectal cancers, but there is uncertainty about SSP
prevalence and clinical features.
NEW FINDINGS
In a systematic review, we found the reported prevalence
of SSPs to be less than 5%, on average, with limited
variation by age and sex. However, prevalence varies
with study location, diagnostic criteria, and examination
quality. SSPs are solitary, large, and proximal relatively
often; the proportion that have dysplasia, based on
cytologic analysis, varied widely across studies, possibly
reflecting population differences.
LIMITATIONS
Cancer risk could not be assessed.
IMPACT
Standardized diagnostic criteria, training, and quality
verification for endoscopists and pathologists should be
considered to ensure adequate SSP detection,
diagnosis and removal. Additional research is needed to
determine differences in prevalence with age and among
different locations, and long-term risk.
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ATresulting in relatively few cancers. Because adenomas are
detectable and removable at endoscopy, CRC is highly
amenable to screening, as was first shown in the National
Polyp Study in 1993.5
More recently, it has been suggested that CRC may also
arise from an alternative pathway with serrated polyp
precursors.6,7 Because serrated polyps were generally
considered innocuous until the World Health Organization
(WHO) included them in its manual for tumor classification
of the digestive system,8 relatively little is known about
their epidemiology and risk.9 The serrated polyp family in-
cludes sessile serrated polyps (SSPs), also known as sessile
serrated adenomas or lesions; traditional serrated ade-
nomas, and hyperplastic polyps. Hyperplastic polyps are the
most common, and, especially, small distal hyperplastic
polyps are not believed to harbor risk of malignancy.
Traditional serrated adenomas are the most rare and can
lead to CRC. SSPs appear to be substantially less common
than adenomas,10 but their associated molecular features
may be overrepresented among CRC cases,11,12 suggesting
potentially higher risk of CRC compared to adenomas.
In this study, we sought to increase clarity on the preva-
lence and clinical features of SSPs by systematically reviewing
the relevant literature from the last 2 decades. Review out-
comes included prevalence by age, sex, and clinical definition;
the multiplicity, size, and localization; and the proportion with
cytologic dysplasia, the pathologic bridge to cancer.Methods
General Study Design
The review was planned and designed in consultation with
Stanford and Erasmus University librarians and consisted of 6steps: (1) defining the scope, (2) literature search, (3) literature
review and selection, (4) quality appraisal, (5) data abstraction,
and (6) statistical analysis. Two different investigators per-
formed steps 3–5 independently, with disagreements resolved
through consensus.
Scope of the Review
We addressed several research questions under 5 main
headers (Supplementary Table 1): the (1) prevalence and
(2) clinical features of SSPs. Specific research questions
under the first header included the prevalence by (1a)
calendar year; (1b) world region; (1c) clinical definition;
(1d) age/sex; (1e) indication for the prevalence assessment
(eg, CRC screening vs follow-up of occult blood in stool);
and (1f) quality of the examination (with high quality
defined as examination with enhanced endoscopes or by
providers from the upper quartile [minimum] of SSP
detection rate). In addition, (1g) the fraction of SSPs among
all potentially precancerous polyps (including adenomas,
SSPs, or traditional serrated adenomas) was also assessed to
gain insight into the relative proportions of polyps vs CRCs
with characteristics of the serrated pathway.13 Specific
research questions under the second header included (2a)
polyp number, (2b) size, (2c) anatomic location, (2d) coex-
istence with adenoma, and (2e) presence and (2f) age at
detection of cytologic dysplasia.
Most research questions focused entirely on SSPs ac-
cording to strict histopathologic criteria.8 Because what is
considered a clinically relevant serrated polyp and patholo-
gists’ attention to the difference between sessile serrated
and hyperplastic polyps have all evolved over time, under
research question 1c, we also considered various more lib-
eral definitions for clinically relevant serrated polyps as
encountered in the literature, including large and/or prox-
imal hyperplastic polyps in addition to the more strict his-
tologic definition. Under research question 1c only, we also
considered inclusion of traditional serrated adenomas. Re-
ported definitions were grouped into 3 different categories:
(1) older terminology used before the 2010 WHO classifi-
cation of tumors,8 consisting of large hyperplastic polyps
(10 mm in diameter), proximal hyperplastic polyps
(located proximal of the splenic flexure), and serrated ade-
nomas (including but not distinguishing SSPs and traditional
serrated adenoma); (2) strict terminology similar to the
histopathologic criteria from the 2010 WHO classification
manual, consisting of only SSPs and traditional serrated
adenomas; and (3) more recently introduced composite
definitions, including clinically relevant histology, size, and
location. The latter category combined SSP and traditional
serrated adenomas, with either any large hyperplastic
polyps (with large distal polyps excluded for some studies)
or any proximal hyperplastic polyps (with large distal
polyps included for some studies).Literature Search
Ovid MEDLINE, Web of Science, Embase, and the Cochrane
database were searched from January 1, 2000, through April
19, 2018, for original studies on serrated polyps written in
English. General search terms were used to minimize the risk of
missed information (Supplementary Table 2).





ATLiterature Review and Selection
Covidence systematic review software was used to manage
references, discard duplicates, review literature, and compare
reviewer decisions. Selection of studies by each reviewer was
based on scanning titles and abstracts, followed by potential
full-text review. Studies were selected according to predefined
criteria for Population, Intervention, Comparison, Outcome,
and Study Design (PICOS) (Supplementary Table 1). The
target population was the US general population, with data
from other world regions included for research question 1a
and 1b and for other research questions if not statistically
significantly different from the United States under 1b. The
intervention was colonoscopy or autopsy with pathologic
assessment of findings. The comparators depended on the
research question and included prevalence data from other
world regions and CRC incidence data14 for research question
1b, alternative definitions for clinically relevant serrated le-
sions for research question 1c, and adenoma data from 11
autopsy studies (identified elsewhere15 and not systematically
reviewed here)16–26 for research questions 1d and 2a–c. The
outcome of interest was the percentage of the population with
SSPs or the percentage of SSPs with the feature of interest,
relying on study criteria for the diagnosis of SSPs. The study
design was cross sectional.
Quality Appraisal
There is no standard instrument for quality appraisal of
prevalence studies. Therefore, we modified a validated tool
designed for the appraisal of studies measuring the prevalence
of lower back pain,27 answering only the 8 of the 10 questions
deemed pertinent to our study design (Supplementary Table 3).
Assessment criteria concerned study characteristics such as the
method of sampling, the case definition, and the study instru-
ment. The overall risk of bias was qualified as low, moderate, or
high depending on the level of confidence in the study
estimates.
Data Abstraction
Data were stored in a spreadsheet template designed to
enable easy cross-reviewer comparison. We collected all rele-
vant outcome data, as well as all study characteristics relevant
to outcome interpretation or subanalyses. For each outcome,
both the numerator and denominator were recorded (eg, the
numbers of patients with polyps and the total study partici-
pants). Age- and sex-specific data were ascertained to the
extent available.
Statistical Analysis
Random-effects regression was used to meta-analyze
outcome data where possible, and t tests (Wald) were
used to examine the differences in outcomes against com-
parators defined in Supplementary Table 1—first for prev-
alence by world region, then for other outcomes, including
all world regions with prevalence not statistically different
from the United States at a standard 5% significance level. Q
and I2 statistics were calculated to measure outcome het-
erogeneity across studies. Bar charts were used with forest
plots to visualize meta-analysis results. Linear models and t
tests (Wald) were used to examine overall and region-
specific trends in prevalence by calendar year. Log-linearmodels were fitted for overall and study-specific trends by
age.
All analyses were performed using R statistical software,




The literature search returned 4462 references through
April 19, 2018 (Supplementary Figure 1). After duplicate
removal, 2123 studies were selected for review. During ab-
stract review, 1669 irrelevant studies were removed. During
full-text review, an additional 380 studies were excluded. In
total, 74 studies on serrated polyps were included, of which
69 reported on prevalence28–96 and 21 reported on clinical
features.28,37,39,47,50,52,55–57,65,67,70,86,88,91,92,97–101 Of the
excluded studies, some were relevant but discarded because
of overlap with larger studies from the same source pop-
ulation.102–107 For the same reason, specific outcomes for
some of the included studies were excluded.
Study Characteristics and Quality Appraisal
All included studies used colonoscopy in combination
with pathology review as the instrument for serrated polyp
detection. No autopsy studies were identified. Study setting
ranged from community hospital to academic medical cen-
ter from 4 different world regions: the United States (n ¼
36), Europe (n ¼ 23), Asia (n ¼ 11), and Australia (n ¼ 4).
Although inclusion criteria varied, studies often included
examinations for screening or symptoms and excluded pa-
tients with a history of polypectomy, CRC, colectomy, fa-
milial risk syndromes, inflammatory bowel disease, or a
recent colon examination. Generally, the study examinations
were performed between 2005 and 2015, diagnostic criteria
were based on the WHO classification manual or various
earlier sources, mean patient age was approximately 60
years, and the average percentages of female patients was
approximately 50%–60%. For details, see Supplementary
Table 4.
Because study enrollment was nonrandom (based on
selection for colonoscopy instead of random sampling of the
general population) and outcome assessment is operator-
dependent (colonoscopy and pathology),49 the risk of bias
for the included studies was judged to be moderate to high
(Supplementary Table 5).
Prevalence of Sessile Serrated Polyps by Study
Publication Year and Size
Few reports on the prevalence of SSPs were published
before 2010, but the number of reports increased dramat-
ically after the serrated polyp was first included in the 2010
WHO manual for tumor classification (Supplementary
Figure 2).8 The range for reported prevalence of SSPs at
colonoscopy across all studies was very broad (0.0; 95%
confidence interval [CI], 0.0–0.1 in Cao et al40 and up to
20.0%; 95% CI; 17.3–23.2 in Bettington et al36). Despite an
increasing awareness of SSPs, there was no significant
108 Meester et al Gastroenterology Vol. 159, No. 1
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ATupward trend in reported prevalence over time across all
studies (þ0.1% per year; 95% CI –0.2 to 0.4; P ¼ .49).
However, trends varied by world region and did increase
among US studies specifically (þ0.3% per year; 95% CI, 0.0–
0.7; P ¼ .03) (Supplementary Figure 2).
Prevalence of Sessile Serrated Polyps by World
Region
The prevalence of SSPs at colonoscopy in the United
States was 5.1% (95% CI, 3.6–6.5) (Supplementary
Figures 3 and 4). Prevalence was higher in Australia
(10.5%; 95% CI, 2.8–18.2; P ¼ .03) but not statistically
different in Asia (2.6%; 95% CI, 0–5.9; P ¼ .14) and Europe
(3.9%; 95% CI, 2.0–5.9; P ¼ .51) compared with the United
States (Supplementary Figures 3 and 4). Excluding 1
extreme statistical outlier,42 the mean prevalence for Asia
was statistically different from the United States (0.9%;
95% CI, 0.5–1.3; P ¼ .004). The pattern in polyp prevalence
across regions was qualitatively similar to the reported CRC
incidence pattern,14 although relative prevalence differ-
ences appear larger (Supplementary Figure 3).
The mean overall prevalence of SSPs at colonoscopy
across all US and European studies was 4.6% (95% CI, 3.4–
5.8) (Figure 1).
The mean fraction of all potentially precancerous polyps
with sessile serrated histology in US and European studies
was 9.4% (95% CI, 6.6–12.3) (Figure 2).
Even within US and European studies there was sub-
stantial heterogeneity in estimates, with study-specific
prevalences ranging from as low as 0.4% (95% CI, 0.0–
0.8)64 to as high as 13.8% (95% CI, 9.0–18.6; Q ¼ 1716; P <
.001) (Figure 1)68 and with the fraction of polyps with
sessile serrated histology ranging from 3.9% (95% CI, 3.3–
4.6)37 to 25.4% (95% CI, 19.5–31.3; Q ¼ 2430, P < .001)
(Figure 2).68
Prevalence According to Definition for Clinically
Relevant Serrated Polyps
Under older terminology, the prevalence of clinically
relevant serrated polyps in US and European studies varied
from 1.8% (95% CI, 1.3–2.2) for large hyperplastic polyps to
3.3% (95% CI, 1.6–5.0) for serrated adenomas, to 8.5%
(95% CI, 6.7–10.4) for proximal serrated polyps (Figure 3
and Supplementary Figure 5). The last was significantly
higher than the prevalence with the strict SSP definition
(4.6%; 95% CI, 3.4–5.8; P < .001).
Under strict terminology, the prevalence of SSPs and
traditional serrated adenomas combined (4.4%; 95% CI,
2.9–5.9) was somewhat lower than the prevalence of only
SSPs (Figure 3), but this difference was not significant (P ¼
.93) and was due to study selection, because not all studies
reported on both histologies. The prevalence of SSPs alone
in the studies reporting on both SSPs and traditional
serrated adenoma was 4.1% (95% CI, 2.6–5.5), suggesting a
net prevalence for traditional serrated adenomas of
approximately 0.3%.
Under more liberal definitions for clinically relevant
histology, size, and location, the prevalence estimates werehigher than under the strict SSP definition, ranging from
5.6% (95% CI, 3.3–7.9; P ¼ .44) for definitions based pri-
marily on histology and large size to 12.3% (95% CI, 9.3–
15.4; P < .001) for definitions based primarily on histology
and proximal location (Figure 3).
Prevalence of Sessile Serrated Polyps According
to Examination Indication and Quality
The prevalence of SSPs in US and European studies
was not related to examination indication, that is,
whether the colonoscopy detecting the polyps was
performed for screening in asymptomatic adults vs for
screening or other indications (4.3%; 95% CI, 2.4–6.1 vs
4.5%; 95% CI, 2.9–6.0; P ¼ .89) (Figure 4 and
Supplementary Figure 6). Although prevalence at a pa-
tient’s initial screening examination was higher (5.3%;
95% CI, 0–11.0; P ¼ .73), this estimate was based on
only 3818 examinations from 2 studies with wide
confidence intervals (Figure 4).
Prevalence was higher when patients were examined by
high polyp detectors or with enhanced endoscopes (9.1%;
95% CI, 4.0–14.2 for these high-performance examinations
vs 4.7%; 95% CI, 3.5–5.9 for unselected examinations; P ¼
.04) (Figure 4 and Supplementary Figure 6). Prevalence was
also higher for examinations with good to excellent bowel
preparation (8.2%; 95% CI, 3.3–13.0), although the differ-
ence vs all examinations was not significant (P ¼ .10)
(Figure 4).
Prevalence of Sessile Serrated Polyps by Age
and Sex
Few US and European studies reported on the preva-
lence of SSPs by age and sex. The age pattern for SSPs
contrasted with that for adenomatous polyps (Figure 5).
SSP prevalence increased with age, but the relative in-
crease was smaller than that for adenoma and did not
reach statistical significance (relatively, þ1.9% per age
year; 95% CI, 0.1–3.9 for 2 studies providing a denomi-
nator; P ¼ .06 vs þ2.7%; 95% CI, 2.0–3.3 for adenomas; P
< .001). Across studies, the relative age increases declined
over time (Supplementary Figure 7 and Supplementary
Tables 6 and 7).
The ratio for the reported prevalence of SSPs in men vs
women of 1.20 (4.9%; 95% CI, 2.8–7.0 for men vs 4.1%;
95% CI, 2.7–5.5 for women; P ¼ .54) (Supplementary
Figures 8 and 9) was comparable to the ratio of 1.19 for
adenomas (39.9%; 95% CI, 31.3–48.6 for men vs 33.4%,
95% CI, 25.9–40.8 for women; P ¼ .35) (Supplementary
Table 8).
Number, Size, and Location of Sessile Serrated
Polyps
The number, size, and localization of sessile serrated vs
adenomatous polyps in US and European studies is pre-
sented in Figure 6.
Compared with adenomatous polyps, SSPs were char-
acterized by a relatively lower multiplicity, with 69.0%
Figure 1. The prevalence
of SSPs across included
studies from the US and
European. Squares indi-
cate means, square size
represents population
size, whiskers show 95%
CIs, and the polygon in-
dicates the pooled mean,
random-effects metare-
gression. ***Significant
heterogeneity (P < .001).





AT(95% CI, 45.9–2.1%; P ¼ .08) (Supplementary Figure 10)
of patients with SSPs vs 43.3% (95% CI, 38.0–48.6)
(Supplementary Table 9) of patients with adenomas hav-
ing only 1 polyp and 14.3% (95% CI, 0–31.3; P ¼ .07) vs
34.0% (95% CI, 28.0–40.0) of those having 3 or more,
respectively.SSPs were somewhat larger on average than adenomas,
with 19.3% (95% CI, 12.4–26.2; P ¼ .13) (Supplementary
Figure 11) vs 13.2% (95% CI, 10.4–16.1) (Supplementary
Table 10) having a diameter of more than 10 mm.
Compared with adenomas, more SSPs were located
proximal to the splenic flexure: 71.5% (95% CI, 63.5–79.5;Figure 2. The fraction of
polyps with sessile
serrated histology across




size, whiskers show 95%
CIs, and the polygon in-







heterogeneity (P < .001).
Figure 3. The prevalence
of serrated polyps ac-
cording to clinical defini-
tion in US and European
studies. Whiskers show










plots and more detail on
polyp definitions. ***Sig-
nificant difference vs SSP
prevalence (P < .001).
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ATP ¼ .008) (Supplementary Figure 12) vs 59.3% (95% CI,
54.3–64.2) (Supplementary Table 11). The proportion of
polyps located in the rectum was similar (P ¼ .77) and less
than 10% for both types of polyps.Sessile Serrated Polyps and Synchronous
Adenoma
Among 2 studies reporting coexistence of adenomas and
SSPs, 49.4% (95% CI, 45.4–53.9) of patients with SSPs hadFigure 4. SSP prevalence
according to examination
indication and quality level
in US and European
studies. Whiskers show
95% CIs. *Significant dif-
ference vs prevalence in
unselected examinations
(P < .05). Good–excellent
bowel preparation was
determined by the Aron-
chick scale, 7–9 Boston
Bowel Preparation Score,
or split dose; high-quality
examinations indicates
enhanced endoscopes or
a provider from the upper
quartile of SSP detection.
See Supplementary
Figure 6 for forest plots
and definitions.adenomas (Supplementary Figure 13), notably more than
the average prevalence of adenoma in autopsy studies
(Supplementary Figure 8).Presence and Age at Detection of Cytologic
Dysplasia in Sessile Serrated Polyps
The proportion of SSPs with reported cytologic dysplasia
ranged from 3.7% to 42.9% across 4 US and 4 European
studies (Figure 7), with an overall mean of 13.9% (95% CI,
Figure 5. The prevalence
of (A) sessile serrated vs
(B) adenomatous polyps
by age. Dots represent
study observations by age,
colors indicate the
different US and European
studies (Supplementary
Tables 6 and 7), size
shows patient denomina-
tor, and the dashed line is
fitted log-linear trend for
ages 40–100 years,
measuring relative in-
crease by age-year. Some
studies in A provided no
patient denominator and
were excluded from trends
and represented with small
constant numbers. ***Sig-
nificant trend (P < .001).





AT4.8–23.0). Although both US and European studies consisted
of a mix of studies including examinations for screening or
other indications (Supplementary Table 4), the proportion
of SSPs with cytologic dysplasia differed between US and
European studies (7.8%; 95% CI, 2.9–12.6 vs 20.6%, 95%
CI, 3.6–37.5; P ¼ .15) (Supplementary Figure 3), possibly
due to relatively more nonscreening examinations in Europe
(Supplementary Table 12). Excluding 1 extreme statistical
outlier,37 the proportion of SSPs with dysplasia decreased to
9.7% (95% CI, 4.5–14.9).
SSPs with dysplasia tended to be reported at higher ages
than SSPs without dysplasia (Supplementary Figure 14 and
Supplementary Table 13). Among 4 US and European
studies reporting age at diagnosis, SSPs without dysplasia
were detected at an average age of 60.8 years, SSPs with
low-grade or any dysplasia at an average age of 65.6 years,
and SSPs with high-grade dysplasia at an average age of 70.2
years.Discussion
We performed a systematic review including meta-
analysis of studies published since 2000 on the prevalence
and clinical features of SSPs to provide perspective into the
potential importance of these lesions. The overall preva-
lence of SSPs in colonoscopy studies varied around the
world. In studies from the United States and Europe, based
on strict histologic definitions, the prevalence was 4.6%
(95% CI, 3.4–5.8), and SSPs accounted for 9.4% (95% CI,
6.6–12.3) of potentially precancerous lesions. Prevalence
estimates were as high as 9.1% when based on high-quality
colonoscopy examinations and 12.3% when also counting
potentially clinically relevant hyperplastic polyps.
Compared with adenomas, SSPs more often presented soli-
tary, with large size and in the proximal colon. SSPs with
dysplasia and high-grade dysplasia were reported at
approximately 5 and 10 years older average ages, respec-
tively, than nondysplastic SSPs.
Figure 6. The (A, B) number, (C, D) size, and (E, F) localization of (A, C, E) sessile serrated vs (A, B, F) adenomatous polyps. US
and European studies. See Supplementary Figures 10–12 for forest plots and Supplementary Tables 9–11 for adenoma data.
Whiskers show 95% CIs. Significant differences for SSP vs adenoma: **P < .01; ***P < .001. Sizes were small (0–5 mm),
medium (6–9 mm), or large (10þmm); location was proximal (cecum, ascending colon, hepatic flexure, transverse colon), distal
(splenic flexure, descending colon, sigmoid colon), or rectal.
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Figure 7. The proportion of SSPs with cytological dysplasia across studies. US and European studies, including nonscreening
indications. Squares indicate means, square size represents population size, whiskers show 95% CIs, and the polygon in-
dicates the pooled mean, random-effects metaregression. US, 7.8% (95% CI, 2.9–12.6) vs European studies, 20.6% (95% CI,
3.6–37.5) (P ¼ .15). For some studies, the relative prevalence of dysplastic vs all SSPs was used as an approximation
(Supplementary Table 12). Excluding 1 outlier,37 the proportion decreased to 9.7% (95% CI, 4.5–14.9); Europe: 13.1% (95%
CI, 0.6–25.5).***Significant heterogeneity (P < .001).





ATThere is no consensus in the literature on which serrated
polyps are clinically relevant, and this has consequences for
the estimates of prevalence and risk. Histologically, SSPs
and hyperplastic polyps may be difficult to distinguish,49,53
creating the potential for misclassification under strict his-
tologic definitions that consider SSPs and traditional
serrated adenomas as the only clinically relevant serrated
polyps.8 More liberal definitions have been proposed to
address this, but studies differ on whether these should
include large,33,57,89 proximal,59,81 or both large and prox-
imal hyperplastic polyps.32,78,97 We report separate results
based on older terminology, strict definitions, and more
liberal definitions to shed light on what can be a confusing
subject.
We found no significant association between SSP
detection and calendar year when all studies were pooled.
However, lower SSP rates in Asia, including in large recent
studies, affected the pooled estimates. Among US studies,
there was a significant upward trend (þ0.3% point/year),
consistent with reports from specific settings.53,65 Differ-
ences in prevalence between Asia and the United States
may be due to practice variation or more fundamental
causes. The lower reported SSP rates in Asia are consistent
with CRC incidence data (Supplementary Figure 3B) and
race-specific data from the United States.65 Further
research on these differences could help elucidate SSP
etiology.
SSP prevalence increased with age, but the increases did
not quite meet the traditional criteria for statistical signifi-
cance, unlike increases for adenoma. The relationship be-
tween SSP prevalence and age may have evolved over time
by period or cohort effects (Supplementary Figure 7), such
as more prior colonoscopies with polypectomy in older
patients or an increased risk of SSPs in younger adults. An
increased risk in younger persons would synchronize with
documented young-onset CRC increases,108 although those
increases were mostly confined to the rectum, where SSPs
are uncommon.Prevalence was not associated with symptomatic in-
dications. This is consistent with previous studies65,109 and
suggests SSPs may cause fewer symptoms than adenomas.
There was substantial heterogeneity in SSP prevalence
across studies, which may be partly due to study biases.
Studies included in this review were judged to have mod-
erate to high risk of bias due to patient selection, detection
bias, and possible misclassification. No studies ascertained
unselected samples from the general population. In the
United States, undergoing a colonoscopy is associated with
socioeconomic indicators, such as health literacy and in-
surance status.110 Patients with a previous screening history
were usually included, which could be associated with lower
SSP prevalence either due to polypectomy earlier in life or
selection of healthy individuals if patients with a poly-
pectomy earlier in life were excluded (Figure 5). Although
colonoscopy is the criterion standard for colon examination,
it may have missed a substantial proportion of serrated
polyps (Figure 4),111 particularly in earlier years
(Supplementary Figure 2). Thus, the true prevalence of
serrated polyps should be considered higher than what is
reported in colonoscopy studies, because it must be cor-
rected by the miss rate. Finally, it may be difficult for pa-
thologists to distinguish sessile serrated from hyperplastic
polyps. Both the endoscopic detection and pathology
assessment of SSPs require training and verification of
quality to ensure adequate diagnosis.
Dysplasia occurred in 3.7%–42.9% of SSPs across
studies in our review. This wide range must be interpreted
with caution (Supplementary Table 12). It may reflect small
sample sizes, population differences in risk behavior (eg,
smoking), or the presence of symptoms signaling dysplastic
but not nondysplastic SSPs. Further research should deter-
mine the true prevalence of dysplastic SSPs in unselected
populations and the effect of risk factors including smoking.
Strengths of this study include the systematic character,
the sensitive search strategy, and the broad scope encom-
passing many relevant questions regarding SSP
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ATepidemiology. The study also has limitations. First, we did
not attempt to reclassify hyperplastic polyps from the era
before awareness of SSPs.112 Although this might reduce the
risk of detection bias and contamination, it is not feasible to
perform histopathology reassessment of all specimens in
these older studies. Few of the reviewed autopsy studies
provided detailed information on hyperplastic polyps. Sec-
ond, although our review addressed several questions
related to SSP risk, such as regarding the size and presence
of dysplasia, we could not directly assess the risk of ma-
lignancy. Our literature search suggests that very few
studies with longitudinal patient follow-up exist. A large
trial following patients after SSP removal is recruiting, but
results are not expected for >10 years,113 and there is no
plan to observe SSPs unresected. Observational data suggest
no higher postpolypectomy risk for SSPs vs adenomas,
whereas features such as large size and dysplasia, which we
estimated to each occur in up to 10%–15% of SSPs, may
increase risk.114–116
In conclusion, although SSP prevalence may be under-
estimated by colonoscopy studies with inherent miss rates,
SSPs appear to be relatively uncommon compared with
adenomas. More standardized diagnostic criteria for clini-
cally relevant serrated polyps, training, and quality verifi-
cation for endoscopists and pathologists are needed to
ensure SSP detection and removal. Additional research is
needed to increase clarity on actual prevalence by age,
variation across settings, and long-term risk with and
without removal.Supplementary Material
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estimates across studies from random-effects meta-regression (see Supplementary Figure 4 for corresponding forest plots),
whiskers represent 95% CIs, and asterisksmark statistically significant differences compared to studies from the United States
at a 5% significance threshold. Excluding 1 statistical outlier,S1 the mean prevalence for Asia was 0.9% (95% CI, 0.4–1.3), also
significantly different from the US prevalence (P ¼ .004). Incidence data were taken from Ferlay et al.S2 No incidence data
specific to the United States were available from this publication, so North American data excluding Central America are
presented instead.
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Supplementary Figure 4. Forest plots of SSP prevalence by world region: (A) Asia, (B) Europe, (C) the United States, and (D)
Australia. Dots represent study means, symbol size represents population size, whiskers represent 95% CIs, and the polygon
represents the pooled mean estimated from random-effects metaregression. In A, For Cao, 2016 (Cao et al40), the number of
SSPs was used as a proxy for the prevalence numerator. The total prevalence of serrated polyps including hyperplastic polyps
in that study was 0.5%. Excluding 1 extreme statistical outlier,S1 the mean prevalence for Asia was 0.9% (95% CI, 0.5–1.3).
118.e4 Meester et al Gastroenterology Vol. 159, No. 1
Supplementary Figure 4. (continued).
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Supplementary Figure 5. Forest plots of SSP prevalence by clinical definition: (A) large hyperplastic polyps, (B) serrated
adenomas, (C) proximal serrated polyps, (D) SSPs, (E) SSPs or traditional serrated adenomas, (F) clinically relevant size or
histology, and (G) clinically relevant location or histology. Dots represent study means, symbol size represents population size,
whiskers represent 95% CIs, and the polygon represents the pooled mean estimated from random-effects meta-regression.
Large indicates >10-mm diameter. Proximal means left of the splenic flexure. In C, Kahi, 2012 (Kahi et al59) partly overlaps with
the 201560 study but used wider selection criteria, justifying independent inclusion here. In D, the prevalence of SSPs in
studies reporting both SSPs and traditional serrated polyps was 4.1% (95% CI, 2.6–5.5). Outcomes in F and G were composite
definitions consisting of clinically relevant histology (sessile serrated or traditional serrated), size (large), and location (prox-
imal). In F, Anderson, 2017b (Anderson et al33) reported the combined prevalence of SSPs, traditional serrated adenoma, distal
hyperplastic polyps >10 mm, and proximal hyperplastic polyps >5 mm in diameter. Payne, 2014 (Payne et al74) combined
prevalence of SSPs or proximal hyperplastic polyps >10 mm. Riverso, 2017 (Riverso et al82) combined SSPs, traditional
serrated adenoma, and proximal hyperplastic polyps > 10 mm. Schreiner, 2010 (Schreiner et al89) combined SSPs, traditional
serrated adenoma, or hyperplastic polyps >10 mm. For other studies, this outcome was derived by adding up the prevalence
of SSPs, traditional serrated adenoma, and large hyperplastic polyps. In G, Anderson, 2013 (Anderson et al31) and Raju, 2013
(Raju et al81) combined prevalence of SSPs, traditional serrated adenomas, and proximal hyperplastic polyps. Anderson,
2017a (Anderson et al32) and Rzouq, 2015 (Rzouq et al96) combined SSPs, traditional serrated adenoma, proximal hyperplastic
polyps, and distal hyperplastic polyps >10 mm. Racho, 2017 (Racho et al78) combined SSPs, traditional serrated adenoma,
proximal hyperplastic polyps, and distal hyperplastic polyps >5 mm. For other studies, this outcome was derived by adding up
prevalence of SSPs, traditional serrated adenoma, proximal, and >10-mm hyperplastic polyps.
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Supplementary Figure 5. (continued).
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Supplementary Figure 5. (continued).
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Supplementary Figure 6. Forest plots of SSP prevalence by examination indication and quality level. Dots represent study
means, symbol size represents population size, whiskers represent 95% CIs, and the polygon represents the pooled mean
estimated from random-effects metaregression. Good-excellent bowel preparation means good-excellent by Aronchick scale,
7–9 Boston Bowel Preparation Score, or preparation according to split-dose regimens. High-quality examination indicates that
it was performed with enhanced endoscopes (eg, cap-assisted) or by providers from the upper quartile (minimum) of SSP
detection rates. More detail is underneath the panels. In E, Clark, 2016 (Clark and Laine43) selected examinations with 7–9
Boston Bowel Preparation Score. Horton, 2016 (Horton et al54) and Radaelli, 2017 (Radaelli et al79) selected examination with
split-dose bowel preparation. Sanaka, 2014 (Sanaka et al86) selected good-excellent preparation by Aronchick scale. In F, data
for the highest detectors were extracted from Ijspeert, 2015 (Ijspeert et al55) (upper quartile of relevant serrate polyp detection
rates); Li, 201765 (upper quintile of SSP detection rates); and Racho, 2017 (Racho et al78) (highest 4/15 SSP detection rates).
From Baek, 2017 (Baek et al35), data for endocuff-assisted colonoscopy were extracted.
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Supplementary
Figure 6. (continued).
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Supplementary
Figure 8. Prevalence of (A)
SSPs vs (B) adenomatous









Supplementary Figure 7. Prevalence of SSPs by age and study period. This plot shows the studies reporting prevalence by
age in Figure 5 by study period (midrange). Denominators were unknown for Abdeljawad, 2015 (Abdeljawad et al28); Buda,
2012 (Buda et al39); and Ijspeert, 2016 (Ijspeert et al56) and fixed at n ¼ 100 for this figure. Different markers of a similar color
represent the age-specific results within each study. Age groups were horizontally spread around the study period’s midrange
years to show the age pattern (from left to right: youngest to oldest), not to convey differences in timing of observations
between individual age groups. Number indicates the relative increase in prevalence by age year.
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Supplementary Figure 9. Forest plot of SSP prevalence by sex. Dots represent study means, symbol size represents pop-
ulation size, whiskers represent 95% CIs, and the polygon represents the pooled mean estimated from random-effects
metaregression.
Supplementary Figure 10. Forest plot of the multiplicity distribution of SSPs. Dots represent study means, symbol size
represents population size, whiskers represent 95% CIs, and the polygon represents the pooled mean estimated from
random-effects metaregression.
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Supplementary Figure 11. Forest plot of the size distribution of SSPs. Dots represent study means, size represents study
population size, whiskers represent 95% CIs, and polygons represent pooled mean estimates from random-effects metare-
gression. Size was divided into small (0–5 mm), medium (6–9 mm), and large (10þ mm).
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Supplementary Figure 12. Forest plot of the location distribution of SSPs. Dots represent study means, size represents study
population size, whiskers represent 95% CIs, and polygons represent pooled mean estimates from random-effects metare-
gression. Location was divided into proximal (cecum, ascending colon, hepatic flexure, transverse colon), distal (splenic
flexure, descending colon, sigmoid colon), and rectal (rectum).
Supplementary Figure 13. Proportion of patients with SSPs with synchronous adenoma. Dots represent study means, size
represents study population size, whiskers represent 95% CIs, and polygons represent pooled mean estimates from random-
effects metaregression.
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Supplementary Figure 14. Age at detection of SSPs with/without cytologic dysplasia. Dots represent study means, colors
represent different studies, and size represents relative population size.
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Supplementary Table 1.Study Selection Criteria (PICOS)
Research question Population Intervention Comparison Outcome Study design





— SSP prevalencea Cross-sectional
a. By calendar year






















2. Clinical features SSP patients Colonoscopy % of SSPs (/patients)f
a. Number vs adenoma 1
2
3þ
b. Size vs adenoma 1–5 mm
6–9 mm
10þ mm

















PICOS, population, intervention, comparison, outcome, study design.
aAmong patients and precancerous polyps. Including traditional serrated adenoma, if not distinguished. Following study
criteria for diagnosis, considering SSPs and serrated adenoma as interchangeable terms.
bIncluding studies without reported SSP prevalence.
cAutopsy studies.
dUnselected examinations vs examinations for screening or initial screening.
eUnselected examinations vs examinations with high polyp detectors or enhanced endoscopes.
fFor 2a and 2d, the denominator is the number of SSP patients.
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Supplementary Table 2.Literature Search
Database Search term Number of records
Ovid MEDLINE ((serrat* ADJ10 (polyp* OR adeno* OR neoplas* OR carcinom* OR cancer* OR lesion* OR
precursor* OR pathway*)).ab,ti.) NOT (abstract* OR book* OR chapter* OR comment* OR
congres* OR dissertation abstract* OR editorial* OR letter* OR news*).pt. AND english.la.
NOT (exp animals/ NOT humans/)
1343
Embase (’serrated polyp’/de OR (serrat* NEAR/10 (polyp* OR adenom* OR neoplas* OR lesion* OR
precursor* OR pathway*)):ab,ti) NOT ([Conference Abstract]/lim OR [Letter]/lim OR [Note]/
lim OR [Editorial]/lim) AND [English]/lim NOT ([animals]/lim NOT [humans]/lim)
1353
Web of Science TS¼("serrated polyp"/de OR (serrat* NEAR/10 (polyp* OR adeno* OR neoplas* OR carcinom*
OR cancer* OR lesion* OR precursor* OR pathway*))) AND LA¼(english) NOT DT¼(Book
OR Book Chapter OR Editorial Material OR Letter OR Meeting Abstract OR News Item OR
Note)
1654
Cochrane Library ((serrat* NEAR/10 (polyp* OR adeno* OR neoplas* OR carcinom* OR cancer* OR lesion* OR
precursor* OR pathway*)):ab,ti)
112
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Supplementary Table 3.Quality Appraisal Tool
Risk of bias item Criteria for answers (circle one option) Additional notes and examples
External validity
1. Was the study’s target popu-
lation a close representation
of the national population in
relation to relevant variables,
e.g. age, sex, occupation?
 Yes (LOW RISK): The study’s target popu-
lation was a close representation of the na-
tional population.
 No (HIGH RISK): The study’s target popula-
tion was clearly NOT representative of the
national population.
The target population refers to the group of people or entities to
which the results of the study will be generalised. Examples:
 The study was a national health survey of people 15 years and
over and the sample was drawn from a list that included all
individuals in the population aged 15 years and over. The
answer is: Yes (LOW RISK).
 The study was conducted in one province only, and it is not
clear if this was representative of the national population. The
answer is: No (HIGH RISK).
 The study was undertaken in one village only and it is clear this
was not representative of the national population. The answer
is: No (HIGH RISK).
2. Was the sampling frame a true
or close representation of the
target population?
 Yes (LOW RISK): The sampling frame was a
true or close representation of the target
population.
 No (HIGH RISK): The sampling frame was
NOT a true or close representation of the
target population.
The sampling frame is a list of the sampling units in the target
population and the study sample is drawn from this list.
Examples:
 The sampling frame was a list of almost every individual within
the target population. The answer is: Yes (LOW RISK).
 The cluster sampling method was used and the sample of
clusters/villages was drawn from a list of all villages in the target
population. The answer is: Yes (LOW RISK).
 The sampling frame was a list of just one particular ethnic group
within the overall target population, which comprised many
groups. The answer is: No (HIGH RISK).
3. Was some form of random
selection used to select the
sample, OR, was a census
undertaken?
 Yes (LOW RISK): A census was undertaken,
OR, some form of random selection was used
to select the sample (e.g. simple random
sampling, stratified random sampling, cluster
sampling, systematic sampling).
 No (HIGH RISK): A census was NOT under-
taken, AND some form of random selection
was NOT used to select the sample.
A census collects information from every unit in the sampling frame.
In a survey, only part of the sampling frame is sampled. In these
instances, random selection of the sample helps minimise study
bias. Examples:
 The sample was selected using simple random sampling. The
answer is: Yes (LOW RISK).
 The target population was the village and every person in the
village was sampled. The answer is: Yes (LOW RISK).
 The nearest villages to the capital city were selected in order to









Risk of bias item Criteria for answers (circle one option) Additional notes and examples
4. Was the likelihood of non-
response bias minimal?
 Yes (LOW RISK): The response rate for the
study was >/¼75%, OR, an analysis was
performed that showed no significant differ-
ence in relevant demographic characteristics
between responders and non-responders
 No (HIGH RISK): The response rate was
<75%, and if any analysis comparing re-
sponders and non-responders was done, it




 The response rate was 68%; however, the researchers did an
analysis and found no significant difference between re-
sponders and non-responders in terms of age, sex, occupation
and socioeconomic status. The answer is: Yes (LOW RISK).
 The response rate was 65% and the researchers did NOT carry
out an analysis to compare relevant demographic characteris-
tics between responders and non-responders. The answer is:
No (HIGH RISK).
 The response rate was 69% and the researchers did an anal-
ysis and found a significant difference in age, sex and socio-
economic status between responders and non-responders.
The answer is: No (HIGH RISK).
Internal validity
5. Were data collected directly
from the subjects (as
opposed to a proxy)?
 Yes (LOW RISK): All data were collected
directly from the subjects.
 No (HIGH RISK): In some instances, data
were collected from a proxy.
A proxy is a representative of the subject. Examples:
 All eligible subjects in the household were interviewed sepa-
rately. The answer is: Yes (LOW RISK).
 A representative of the household was interviewed and ques-
tioned about the presence of low back pain in each household
member. The answer is: No (HIGH RISK).
6. Was an acceptable case defi-
nition used in the study?
 Yes (LOW RISK): An acceptable case defi-
nition was used.
 No (HIGH RISK): An acceptable case defini-
tion was NOT used.
 For a study on low back pain, the following case definition was
used: “Low back pain is defined as activity-limiting pain lasting
more than one day in the area on the posterior aspect of the body
from the bottom of the 12th rib to the lower gluteal folds.” The
answer is: Yes (LOW RISK).
 For a study on back pain, there was no description of the specific
anatomical location “back‟ referred to. The answer is: No (HIGH
RISK).
 For a study on osteoarthritis, the following case definition was
used: “Symptomatic osteoarthritis of the hip or knee, radiologi-
cally confirmed as Kellgren-Lawrence grade 2-4”. The answer is:
LOW RISK.
7. Was the study instrument that
measured the parameter of in-
terest (e.g., prevalence of low
back pain) shown to have
reliability and validity (if
necessary)?
 Yes (LOW RISK): The study instrument had
been shown to have reliability and validity (if
this was necessary), e.g. test-retest, piloting,
validation in a previous study, etc.
 No (HIGH RISK): The study instrument had
NOT been shown to have reliability or validity
(if this was necessary).
 The authors used the COPCORD questionnaire, which had pre-
viously been validated. They also tested the inter-rater reliability of
the questionnaire. The answer is: Yes (LOW RISK).
 The authors developed their own questionnaire and did not test









Supplementary Table 4. Study Characteristics
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Supplementary Table 3.Continued
Risk of bias item Criteria for answers (circle one option) Additional notes and examples
8. Was the same mode of data
collection used for all
subjects?
 Yes (LOW RISK): The same mode of data
collection was used for all subjects.
 No (HIGH RISK): The same mode of data
collection was NOT used for all subjects.
The mode of data collection is the method used for collecting
information from the subjects. The most common modes are
face-to-face interviews, telephone interviews and self-
administered questionnaires. Examples:
 All eligible subjects had a face-to-face interview. The answer is:
Yes (LOW RISK).
 Some subjects were interviewed over the telephone and some
filled in postal questionnaires. The answer is: No (HIGH RISK).
9. Was the length of the short-
est prevalence period for the
parameter of interest
appropriate?
 Yes (LOW RISK): The shortest prevalence
period for the parameter of interest was
appropriate (e.g. point prevalence, one-week
prevalence, one-year prevalence).
 No (HIGH RISK): The shortest prevalence
period for the parameter of interest was not
appropriate (e.g. lifetime prevalence)
The prevalence period is the period that the subject is asked about
e.g. “Have you experienced low back pain over the previous
year?” In this example, the prevalence period is one year. The
longer the prevalence period, the greater the likelihood of the
subject forgetting if they experienced the symptom of interest
(e.g. low back pain). Examples:
 Subjects were asked about pain over the past week. The
answer is: Yes (LOW RISK).
 Subjects were only asked about pain over the past three years.
The answer is: No (HIGH RISK).




 Yes (LOW RISK): The paper presented
appropriate numerator(s) AND denominator(s)
for the parameter of interest (e.g. the preva-
lence of low back pain).
 No (HIGH RISK): The paper did present nu-
merator(s) AND denominator(s) for the
parameter of interest but one or more of
these were inappropriate.
There may be errors in the calculation and/or reporting of the
numerator and/or denominator. Examples:
 There were no errors in the reporting of the numerator(s) AND
denominator(s) for the prevalence of low back pain. The answer
is: Yes (LOW RISK).
 In reporting the overall prevalence of low back pain (in both men
and women), the authors accidentally used the population of
women as the denominator rather than the combined popula-
tion. The answer is: No (HIGH RISK).
11. Summary item on the overall risk of study bias
 LOW RISK OF BIAS: Further research is very unlikely to change our confidence in the estimate.
 MODERATE RISK OF BIAS: Further research is likely to have an important impact on our confidence in the estimate and may change the estimate.
 HIGH RISK OF BIAS: Further research is very likely to have an important impact on our confidence in the estimate and is likely to change the estimate.
NOTE. This questionnaire is reprinted from Hoy et al.27 Questions 5 and 9 were not used.








Supplementary Table 7.Adenoma Prevalence by Age Across Autopsy Studies
Study N
Age, y
20–24 25–29 30–34 35–39 40–44 45–49 50–54 55–59 60–64 65–69 70–74 75–79 80–84 85þ
Arminski, 196116,a 1000 2/14 / 9/39 / 23/123 / 66/245 / 107/309 / 88/189 / 36/81 /
Blatt,17 1961 448 — — 0/13 / 4/23 / 18/53 / 38/106 / 71/158 / 41/95 /
Bombi,18 1988 212 5/42 / / / / / 7/28 / 10/36 / 15/59 / 9/47 /
Chapman,19 1963 443 0/2 / 1/5 / 4/20 / 20/64 / 72/118 / 73/137 / 56/95 /
Clark et al,20 1985 680 — — — — — 17/152 / 27/147 / 54/184 / 76/197 / /
Eide and Stalsberg,21 1978 280 — — — — — 15/52 / 12/49 / 31/83 / 46/96 / /
Jass et al,22 1992 297 0/42 / 2/29 / 3/27 / 14/42 / 15/50 / 21/60 / 17/47 /
Rickert et al,23 1979 518 — — — — 11/65 / 19/59 25/67 31/64 48/76 42/69 28/55 39/63 /
Stemmerman and Yatani,24 1973 202 — — — — 6/14 / 1/25 / 32/54 / 34/55 / 35/54 /
Vatn and Stalsberg,25 1982 445 — — — — 3/45 / 23/100 / 31/100 / 44/100 / 47/100 /
Williams et al,26 1982 365 — — — — — 15/82 / 20/69 / 43/108 / 43/106 / /
NOTE. Arrows convey that no specific number was reported for a particular cell and that numbers printed to the left apply. For studies not specifying the lower age range,
this was assumed to have a similar width as the other age ranges.
RR, relative risk.
aRectal adenoma were not included in Arminski, 1961, suggesting true prevalence of adenomas in the colon and rectum may be higher.
Supplementary Table 6.SSP Prevalence by Age Across Studies
Study Region N
Age, y
40–44 45–49 50–54 55–59 60–64 65–69 70–74 75–79 80–84 85þ
With denominator
Li et al,65 2018 United States 34,161 102/5102 / 387/10470 / 475/11314 / 265/5890 / 48/1385 /
Schramm et al,88 2016 Europe 1694 — 11/460 / 9/610 / 21/532 / — — —
Other studies
Abdeljawad et al,28 2015 United States 1910 — — 6.8% / 8.9% / 5.3% / 15.2% /
Buda et al,39 2012 Europe 985 OR:1 / OR:5.8 / OR:5.8 / OR:9.3 / — —
Ijspeert et al,56 2016 Europe 3364 6.0% / 8.3% / 9.0% / 8.4% / — —



















with 1þ polyps, n
Arminski, 196116 575 198 425 134
Blatt,17 1961 248 99 198 73
Clark et al,20 1985 370 103 310 71
Eide and Stalsberg,21 1978 171 68 109 36
Jass et al,22 1992 185 47 118 25
Rickert et al,23 1979 307 162 211 81
Stemmermann and Yatani,24 1973 125 80 77 45
Williams et al,26 1982 198 73 167 48
Supplementary Table 9.Adenoma Multiplicity Distribution Across Autopsy Studies
Study Patients, n Patients with 1 polyp, n Patients with 2 polyps, n Patients with 3þ polyps, n
Blatt,17 1961 173 72 41 60
Stemmerman and Yatani,24 1973 125 50 26 49
Eide and Stalsberg,21 1978 104 52 23 29
Supplementary Table 10.Adenoma Size Distribution Across Autopsy Studies







Arminski, 196116 647 379 169 99
Blatt,17 1961 465 232 158 75
Bombi,18 1988 89 41 42 6
Eide and Stalsberg,21 1978 280 123 133 24
Jass et al,22 1992 149 58 64 27
Rickert et al,23 1979 629 275 257 97
Williams et al,26 1982 242 103 108 31
Supplementary Table 11.Adenoma Location Distribution Across Autopsy Studies
Study Total polyps, n Proximal polyps, n Distal polyps, n Rectal polyps, n
Arminski, 196116 797 368 279 150
Blatt,17 1961 465 285 145 35
Bombi,18 1988 89 50 32 7
Chapman,19 1963 552 349 188 15
Clarke,20 1985 680 380 245 54
Eide and Stalsberg,21 1978 280 153 102 25
Rickert et al,23 1979 629 424 158 47
Stemmerman and Yatani,24 1973 328 216 91 21
Williams et al,26 1982 242 139 71 32
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Supplementary Table 12.Characteristics of Studies Reporting Dysplasia in SSPs




examinations, % Polyps or patientsa N Dysplasia, % Large, %
Abdeljawad et al,28 2015 North America Screening 100 0 Patients 225 5.8 22.7
Bouwens et al,37 2014 Europe Screening, symptoms,
or surveillance
0–6.9 93.1–100 Polyps 140 42.9 —
Hazewinkel et al,52 2014 Europe Screening (trial) 100 0 Polyps 111 26.1 23.5b
Ijspeert et al,56 2016 Europe Any except screening 0 100 Polyps 399 3.8 21.4
Ijspeert et al,57 2017 Europe Screening, or FTþ patients 34 66 Patients 1049 11.0 30.0
Lash et al,98 2010 North America Any Unknown Unknown Patients 2139 15.1 —
Pai et al,99 2010 North America Screening 100 0 Polyps 68 7.4 —
Turner et al,92 2018 North America Any Unknown Unknown Polyps 25,848 3.7 33.6
FTþ, positive fecal test result.
aProportion of polyps or patients.
bProportion of patients with SSPs who have large SSPs.
Supplementary Table 13.Age at Detection of SSPs Across Studies
Study Region Patients, N
Age at Diagnosis of
SSPs With no Dysplasia, y
Age at Diagnosis of SSPs
With Any Dysplasia, y
Age at Diagnosis of
SSPs With High-Grade Dysplasia, y
Bouwens et al,37 2014 Europe 140 61 66 —
Lash et al,98 2010 United States 2139 61 66 72
Pai et al,99 2010 United States 68 62.6 60.7
Yang et al,101 2015a United States 11,201 60.8 65.6 69.9
Averageb 13,548 60.8 65.6 70.2
aNot included in Figure 7 of the article, the meta-analysis of prevalence of cytologic dysplasia in SSPs, because of overlap with Turner et al.92
bAverage across studies weighted by study size.
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